Poop pills may reboot liver cancer therapy

NCT ID NCT07276100

Recruiting now Disease control Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a fecal microbiota transplant (FMT) can help liver cancer patients who stopped responding to standard drugs. Fifteen adults with advanced liver cancer will receive FMT along with atezolizumab and bevacizumab to see if the combination can restore tumor control. The trial focuses on safety and whether the disease stabilizes or shrinks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fecal microbiota transplantation (FMT) combined with atezolizumab and bevacizumab
What this could lead to: If it works, this could offer a new option for liver cancer patients whose disease worsened on standard treatment, potentially restoring the effectiveness of their therapy.
What could go wrong: This is a very small early-phase trial with only 15 participants, so results may not apply broadly. FMT carries risks of infection or other side effects, and the combination may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

IRCCS AOU di Bologna Policlinico di Sant'Orsola
RECRUITING

Bologna, BO, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.